ABT - Abbott Laboratories
A diversified healthcare company spanning diagnostics, medical devices, nutrition, and established pharmaceuticals, with a strong presence in rapid testing and cardiac devices.
Finlify Score
13.8 / 100
Data Quality
PARTIAL
Penalty
-1.0
Sector
Health Care
Close Price
$88.67
+0.56%
52W Range
$81.97 - $139.06
Market Cap
$149.1B
+0.6%Compared to previous day
2026 Q1 Revenue
$11.2B
-2.6%Changes from last reporting quarter
2026 Q1 EPS
$0.00
Diluted shares
Analyst Rating
34 analysts in latest ratings feed
RSI
56.6
40-70 moderate
2Y Range Position
11%
-37.2% from high / +8.2% from low
Beta
0.60
Relative to market benchmark
MACD
0.44
MACD line -0.22 / signal line -0.66
Fundamental Trend
Growth 8.7Financial Health
Quality 44.8Data Quality
PARTIALValuation Reference
Price Chart
Close price, two-year source window
Finlify Score
AVOID13.8 / 100
Score History
Finlify Score and component trend
Financial Statements
Calendar year view. Figures are estimates only. For official figures, refer to the company website.
| 2026 Q1 | 2025 Q4 | 2025 Q3 | 2025 Q2 | |
|---|---|---|---|---|
| Revenue | $11.2B-2.6% | $11.5B+0.8% | $11.4B+2.0% | $11.1B+7.6% |
| Gross Profit | - | - | - | - |
| Operating Income | $1.3B-40.2% | $2.3B+9.4% | $2.1B+0.2% | $2.1B+21.2% |
| Net Income | $1.1B-39.4% | $1.8B+8.0% | $1.6B-7.6% | $1.8B+34.3% |
Columns use the calendar quarter of each reported period end date. QoQ is shown for adjacent company reporting quarters only.
AI Signal
Generated Jun 16, 2026
The Finlify signal for ABT is AVOID, with a low Finlify Score of 13.6/100, suggesting a generally unfavorable quantitative outlook. The data quality is PARTIAL, which may limit the overall confidence in the signal due to a -1.0 deduction and the use of an EPS proxy.
Technical
The technical components appear weak, with Relative Strength at 5.5/100 and Accumulation / Volume at 2.2/100, which may indicate limited buying pressure. While the 20-day return shows a positive 3.9%, the asset has experienced a significant 60-day return of -18.7% and is currently -35.5% from its 52-week high, suggesting recent underperformance.
Fundamentals
Fundamental Trend scores very low at 8.7/100, while Financial Quality is 44.8/100, which may suggest some underlying fundamental concerns. The asset trades at a P/E of 23.5x and a P/B of 4.2x, with a Beta of 0.6 indicating lower volatility compared to the broader market, and offers a dividend yield of 2.81%.
Macro Context
The current macro environment, characterized by elevated inflation with CPI YoY at 4.3% and Core PCE YoY at 3.3%, along with a 10Y Treasury Yield of 4.5%, may present challenges for growth-oriented sectors like healthcare. A 0.4% yield spread (10Y-2Y) could suggest a cautious economic outlook.
Key Risks
- The Finlify Score of 13.6/100, driven by very low Relative Strength (5.5/100), Accumulation / Volume (2.2/100), and Fundamental Trend (8.7/100), suggests a weak quantitative profile.
- Significant recent price depreciation, with a -18.7% return over 60 days and the asset trading -35.5% from its 52-week high, indicates potential negative momentum.
- The PARTIAL data quality, including a -1.0 deduction and the use of an EPS proxy, may introduce limitations to the completeness and accuracy of the quantitative assessment.